Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Finished Goods: 2021-2025

Historic Finished Goods for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Sep 2025 value amounting to $2.8 million.

  • Mirum Pharmaceuticals' Finished Goods fell 37.37% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 37.37%. This contributed to the annual value of $3.3 million for FY2024, which is 65.22% down from last year.
  • Mirum Pharmaceuticals' Finished Goods amounted to $2.8 million in Q3 2025, which was down 23.22% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Finished Goods ranged from a high of $11.3 million in Q3 2023 and a low of $87,000 during Q4 2021.
  • Over the past 3 years, Mirum Pharmaceuticals' median Finished Goods value was $3.7 million (recorded in 2025), while the average stood at $4.9 million.
  • Its Finished Goods has fluctuated over the past 5 years, first soared by 6,200.00% in 2023, then slumped by 65.22% in 2024.
  • Mirum Pharmaceuticals' Finished Goods (Quarterly) stood at $87,000 in 2021, then surged by 145.98% to $214,000 in 2022, then skyrocketed by 4,311.68% to $9.4 million in 2023, then plummeted by 65.22% to $3.3 million in 2024, then plummeted by 37.37% to $2.8 million in 2025.
  • Its Finished Goods was $2.8 million in Q3 2025, compared to $3.7 million in Q2 2025 and $3.6 million in Q1 2025.